Briganix 180 mg (Brigatinib) is a cutting-edge oral medication designed to treat ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in ALK-positive lung cancer. This medication is particularly effective for patients whose cancer has progressed…
Briganix 90 mg (Brigatinib) is an advanced oral medication specifically designed for the treatment of ALK-positive non-small cell lung cancer (NSCLC) in adults. Brigatinib is a next-generation tyrosine kinase inhibitor (TKI) that targets the abnormal anaplastic lymphoma kinase (ALK) gene mutation, a key driver of cancer cell growth in some forms of lung cancer. Briganix 90 mg is especially effective…
Lorbrexen (Lorlatinib 100mg) is an innovative cancer therapy specifically designed to treat non-small cell lung cancer (NSCLC) that is positive for ALK (anaplastic lymphoma kinase) mutations. This targeted therapy is highly effective in managing advanced stages of ALK-positive NSCLC, especially in patients whose cancer has progressed despite prior treatment with other ALK inhibitors. Lorbrexen works by blocking the activity of…
